Inhibrx Announces Presentations at SITC 2021
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Society for Immunotherapy of Cancer's annual meeting from November 10-14, 2021, presenting three posters on its clinical candidates. The presentations include data on INBRX-105 and INBRX-106, focusing on pharmacodynamic biomarkers and anti-tumor activity. Additionally, the emerging candidate INBRX-121 will be introduced, targeting NK cells to enhance cytotoxicity. These highlights reflect Inhibrx's ongoing commitment to advancing oncology therapeutics.
- Presentation of three significant clinical candidate posters at SITC 2021.
- Introduction of INBRX-121, a new candidate targeting NK cells.
- None.
SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer's (SITC) annual meeting, to be held in Washington, D.C. and in a virtual platform, on November 10-14, 2021.
"We are excited to share some of the preclinical data related to our clinical candidates, INBRX-105 and INBRX-106, which inform the selection of pharmacodynamic biomarkers, dosing and clinical strategy," said Brendan Eckelman, Ph.D., Inhibrx Co-founder and Chief Scientific Officer.
"Additionally, we will be introducing the first emerging pipeline candidate from our targeted cytokine platform, INBRX-121, which specifically expands and enhances the cytotoxic capacity of NK cells."
Poster Presentation Details:
Title: INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors
Lead Author: Emily Rowell, Ph.D.
Category: Novel Single-Agent Immunotherapies
Abstract: 856
Session Date & Time: ePoster on display beginning Friday, November 12th; 7:00 a.m. EST
Title: INBRX-105- Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist
Lead Author: Heather Kinkead, Ph.D.
Category: Biomarkers, Immune Monitoring, and Novel Technologies
Abstract: 12
Session Date & Time: Saturday, November 13th; 7:00 a.m.- 8:30 p.m. EST
Title: INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities
Lead Author: Florian J. Sulzmaier, Ph.D.
Category: Immune-Stimulants and Immune Modulators
Abstract: 722
Session Date & Time: Saturday, November 13th; 7:00 a.m.- 8:30 p.m. EST
The scientific posters will be accessible through the following link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with 2seventy bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-presentations-at-sitc-2021-301415015.html
SOURCE Inhibrx Inc.
FAQ
What will Inhibrx present at the SITC 2021 annual meeting?
When is the SITC 2021 annual meeting?
What is INBRX-121?
What type of data will be shared regarding INBRX-105 and INBRX-106?
